Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","amount":"$89.0 million","upfrontCash":"$25.0 million","newsHeadline":"Santen and RVL Pharmaceuticals Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq for Acquired Blepharoptosis (Droopy Eyelid) in Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Osmotica's Upneeq\u2122 for Acquired Ptosis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$110.0 million","newsHeadline":"Osmotica Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Athyrium Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"$27.5 million","newsHeadline":"Novan Acquires EPI Health, a Specialty Dermatology Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revision Skincare\u00ae Announces Strategic Partnership with RVL Pharmaceuticals, Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$5.0 million","newsHeadline":"EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE\u00ae in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Afrin\u00ae WOWs Parents with Launch of Children\u2019s Acute Medicated Nasal Sprays \u2013 Because One Sick Kid Can Throw Everything Off in An Instant","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levation Pharma Initiates Phase I\/II Clinical Trial of LEV102 for Acquired Blepharoptosis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Oxymetazoline

    Menu

    Oxymetazoline

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Levation Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis

              Details:

              LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharoptosis.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: LEV102

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EPI Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan

              Details:

              Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Dermatology Product Name: Rhofade

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd

              Deal Size: $7.5 million Upfront Cash: $5.0 million

              Deal Type: Licensing Agreement December 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bayer AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Throw Everything Off in An Instant

              Details:

              Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Afrin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Revision Skincare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.

              Details:

              As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Upneeq

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: RVL Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership August 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RVL Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing

              Details:

              The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Upneeq

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Athyrium Capital

              Deal Size: $24.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement August 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EPI Health

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novan Acquires EPI Health, a Specialty Dermatology Company

              Details:

              Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Dermatology Product Name: Rhofade

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novan

              Deal Size: $51.0 million Upfront Cash: $27.5 million

              Deal Type: Acquisition March 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Osmotica Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

              Details:

              The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Upneeq

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Athyrium Capital Management

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing October 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Osmotica Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Osmotica Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC

              Details:

              Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Upneeq

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Alora Pharmaceuticals

              Deal Size: $170.0 million Upfront Cash: $110.0 million

              Deal Type: Divestment June 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Osmotica Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Osmotica's Upneeq™ for Acquired Ptosis

              Details:

              Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Upneeq

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Santen Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Santen and RVL Pharmaceuticals Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201

              Details:

              Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.

              Lead Product(s): Oxymetazoline Hydrochloride

              Therapeutic Area: Ophthalmology Product Name: Upneeq

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: RVL Pharmaceuticals

              Deal Size: $89.0 million Upfront Cash: $25.0 million

              Deal Type: Licensing Agreement July 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY